News & Updates

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

22 Jan 2021 by

Romilkimab – a novel engineered, humanized immunoglobulin(Ig)-G4 antibody – delivers significant skin benefits for individuals with early diffuse cutaneous systemic sclerosis (dcSSc), a subtype of SSc, a phase II proof-of-concept study has shown.

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

22 Jan 2021

IL-6, TNF-α up mortality risk in hospitalized cancer patients with rash

20 Jan 2021

Hospitalized cancer patients with rash and elevated interleukin (IL)-6 and tumour necrosis factor (TNF)-α have a sixfold increased risk of mortality over the course of follow-up, according to a recent study.

IL-6, TNF-α up mortality risk in hospitalized cancer patients with rash

20 Jan 2021

Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS

19 Jan 2021 by

The efficacy and safety of long-term tildrakizumab are comparable and maintained without evidence of reduced durability of response through 148 weeks of treatment in patients with and without metabolic syndrome (MetS), results from two phase III trials have shown.

Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS

19 Jan 2021

Biologic treatments for psoriasis protect against COVID-19 hospitalization

15 Jan 2021

Among patients with moderate-to-severe psoriasis, the use of biologics appears to lower the risk of being hospitalized for the novel coronavirus disease (COVID-19), a new study has found.

Biologic treatments for psoriasis protect against COVID-19 hospitalization

15 Jan 2021

Managing paediatric eczema in primary care

06 Jan 2021

There is a high burden of paediatric eczema in the primary care setting. Dr Liew Hui Min, a consultant dermatologist from SOG-HM Liew Skin & Laser Clinic at Gleneagles Hospital, Singapore, shares her insights with Pearl Toh on how to manage paediatric eczema in the primary care setting.

Managing paediatric eczema in primary care

06 Jan 2021

Are isotretinoin-exposed patients with acne vulgaris prone to new-onset IBD?

05 Jan 2021

There appears to be a low incidence of inflammatory bowel disease (IBD) among patients with acne vulgaris (AV) exposed to isotretinoin, according to a recent study. Additionally, the risk is similar to that for unexposed patients with AV.

Are isotretinoin-exposed patients with acne vulgaris prone to new-onset IBD?

05 Jan 2021

Taking calcium supplements reduces risk of squamous cell carcinoma

30 Dec 2020

Treatment with calcium supplementation with or without vitamin D appears to lower the risk of invasive cutaneous squamous cell carcinoma (SCC) but not basal cell carcinoma (BCC), a study has shown.

Taking calcium supplements reduces risk of squamous cell carcinoma

30 Dec 2020

Biologics cut mortality risk in psoriasis regardless of treatment duration

19 Dec 2020

In patients with moderate-to-severe psoriasis, biologic agents seem to reduce mortality risk regardless of treatment duration, a recent study has found. Methotrexate, on the other hand, only shows a similar efficacy when used for at least a year.

Biologics cut mortality risk in psoriasis regardless of treatment duration

19 Dec 2020

Upadacitinib improved symptoms, QoL in moderate-to-severe AD

16 Dec 2020 by

Upadacitinib monotherapy improved symptoms and quality of life (QoL) in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the phase III Measure Up 1 and 2 studies presented at EADV 2020.

Upadacitinib improved symptoms, QoL in moderate-to-severe AD

16 Dec 2020

Frequent energy-drink consumption tied to asthma, allergic rhinitis, atopic dermatitis

12 Dec 2020

Regular consumption of energy drinks may lead to allergic diseases, such as asthma, allergic rhinitis, and atopic dermatitis, according to a cross-sectional study in Korea.

Frequent energy-drink consumption tied to asthma, allergic rhinitis, atopic dermatitis

12 Dec 2020

News & Updates

Filter by Specialty:

Specialty:

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

Romilkimab shows potential for early diffuse cutaneous systemic sclerosis

IL-6, TNF-α up mortality risk in hospitalized cancer patients with rash

IL-6, TNF-α up mortality risk in hospitalized cancer patients with rash

Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS

Long-term tildrakizumab safe, effective in psoriatic patients with or without MetS

Biologic treatments for psoriasis protect against COVID-19 hospitalization

Biologic treatments for psoriasis protect against COVID-19 hospitalization

Managing paediatric eczema in primary care

Managing paediatric eczema in primary care

Are isotretinoin-exposed patients with acne vulgaris prone to new-onset IBD?

Are isotretinoin-exposed patients with acne vulgaris prone to new-onset IBD?

Taking calcium supplements reduces risk of squamous cell carcinoma

Taking calcium supplements reduces risk of squamous cell carcinoma

Biologics cut mortality risk in psoriasis regardless of treatment duration

Biologics cut mortality risk in psoriasis regardless of treatment duration

Upadacitinib improved symptoms, QoL in moderate-to-severe AD

Upadacitinib improved symptoms, QoL in moderate-to-severe AD

Frequent energy-drink consumption tied to asthma, allergic rhinitis, atopic dermatitis

Frequent energy-drink consumption tied to asthma, allergic rhinitis, atopic dermatitis